Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006

Journal of Heart and Lung Transplantation

Volumn 25, Issue 9, 2006, Pages 1003-1023

  Jessup, Mariell ^a   Banner, Nicholas ^a   Brozena, Susan ^a   Campana, Carlo ^a   Costard Jäckle, Angelika ^a   Dengler, Thomas ^a   Hunt, Sharon ^a   Metra, Marco ^a   Rahmel, Axel ^a   Renlund, Dale ^a   Ross, Heather ^a   Warner Stevenson, Lynne ^a  

^a International Society for Heart and Lung Transplantation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FUROSEMIDE; HYDRALAZINE; HYPERTENSIVE AGENT; LOOP DIURETIC AGENT; LOSARTAN; METOLAZONE; METOPROLOL SUCCINATE; NESIRITIDE; NITRATE; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VASOCONSTRICTOR AGENT;

ANGIONEUROTIC EDEMA; ARTICLE; CARDIOGENIC SHOCK; CARDIOTOXICITY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COUGHING; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE MARKER; EXERCISE; FLUID RETENTION; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; LIVER TOXICITY; LUNG TRANSPLANTATION; METHODOLOGY; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SLEEP DISORDER;

EID: 33748626882     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.06.007     Document Type: Article

References (267)

1. Nieminen M.S., Bohm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416
2. Cosin J., and Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4 (2002) 507-513
3. Neuberg G.W., Miller A.B., O'Connor C.M., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002) 31-38
4. De Bruyne L.K. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J 79 (2003) 268-271
5. Channer K.S., McLean K.A., Lawson-Matthew P., and Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 71 (1994) 146-150
6. Dormans T.P., and Gerlag P.G. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 17 (1996) 1867-1874
7. Eichhorn E.J., and Bristow M.R. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 94 (1996) 2285-2296
8. Swedberg K. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Eur J Heart Fail 2 (2000) 229-233
9. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 (2001) 1689-1697
10. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 21 (2002) 189-203
11. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 (2003) 2007-2018
12. Remme W.J., and Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560
13. Bristow M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101 (2000) 558-569
14. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 77 (1988) 721-730
15. Stevenson L.W. Beta-blockers for stable heart failure. N Engl J Med 346 (2002) 1346-1347
16. Flather M.D., Yusuf S., Kober L., et al., ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355 (2000) 1575-1581
17. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
18. Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation 77 (1988) I-64-I-73
19. Packer M., Lee W.H., Kessler P.D., Medina N., Yushak M., and Gottlieb S.S. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 10 (1987) 837-844
20. Packer M., Lee W.H., Medina N., Yushak M., and Kessler P.D. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 106 (1987) 346-354
21. Mann J.F., Gerstein H.C., Pogue J., Bosch J., and Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134 (2001) 629-636
22. Kittleson M., Hurwitz S., Shah M.R., et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 41 (2003) 2029-2035
23. Gring C.N., and Francis G.S. A hard look at angiotensin receptor blockers in heart failure. J Am Coll Cardiol 44 (2004) 1841-1846
24. McMurray J.J., Pfeffer M.A., Swedberg K., and Dzau V.J. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?. Circulation 110 (2004) 3281-3288
25. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
26. Maggioni A.P., Anand I., Gottlieb S.O., Latini R., Tognoni G., and Cohn J.N. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40 (2002) 1414-1421
27. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
28. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
29. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
30. Pitt B., Zannad F., Remme W.J., et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
31. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
32. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
33. Metra M., Nodari S., and Dei C.L. Current guidelines in the pharmacological management of chronic heart failure. J Renin Angiotensin Aldosterone Syst 5 suppl 1 (2004) S11-S16
34. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
35. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
36. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
37. Erdmann E., Lechat P., Verkenne P., and Wiemann H. Results from post hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3 (2001) 469-479
38. Goldstein S., Fagerberg B., Hjalmarson A., et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 38 (2001) 932-938
39. Krum H., Roecker E.B., Mohacsi P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 289 (2003) 712-718
40. Krum H., Ninio D., and MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 84 (2000) 615-619
41. Macdonald P.S., Keogh A.M., Aboyoun C.L., Lund M., Amor R., and McCaffrey D.J. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 33 (1999) 924-931
42. Rouleau J.L., Roecker E.B., Tendera M., et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 43 (2004) 1423-1429
43. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., and Dei C.L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2001) 546-551
44. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
45. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
46. Gattis W.A., O'Connor C.M., Leimberger J.D., Felker G.M., Adams K.F., and Gheorghiade M. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 91 (2003) 169-174
47. Metra M., Torp-Pedersen C., and Charlesworth A. Should beta-blocker therapy be reduced or withdrawn in patients with worsening heart failure?. Insights from COMET. Circulation 110 (2004) III-430
48. Nohria A., Lewis E., and Stevenson L.W. Medical management of advanced heart failure. JAMA 287 (2002) 628-640
49. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
50. Packer M., Gheorghiade M., Young J.B., et al., RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med 329 (1993) 1-7
51. Uretsky B.F., Young J.B., Shahidi F.E., Yellen L.G., Harrison M.C., Jolly M.K., and PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 22 (1993) 955-962
52. DiBianco R., Shabetai R., Kostuk W., Moran J., Schlant R.C., and Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320 (1989) 677-683
53. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
54. Rathore S.S., Wang Y., and Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347 (2002) 1403-1411
55. Farshi R., Kistner D., Sarma J.S., Longmate J.A., and Singh B.N. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 33 (1999) 304-310
56. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
57. Eichhorn E.J., Lukas M.A., Wu B., and Shusterman N. Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure. Am J Cardiol 86 (2000) 1032-1
58. Adamopoulos S., Parissis J.T., and Kremastinos D.T. New aspects for the role of physical training in the management of patients with chronic heart failure. Int J Cardiol 90 (2003) 1-14
59. Coats A.J., Adamopoulos S., Radaelli A., et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 85 (1992) 2119-2131
60. Malfatto G., Branzi G., Riva B., Sala L., Leonetti G., and Facchini M. Recovery of cardiac autonomic responsiveness with low-intensity physical training in patients with chronic heart failure. Eur J Heart Fail 4 (2002) 159-166
61. Pina I.L., Apstein C.S., Balady G.J., et al. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 107 (2003) 1210-1225
62. Leon A.S., Franklin B.A., Costa F., et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation 111 (2005) 369-376
63. Taylor R.S., Brown A., Ebrahim S., et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116 (2004) 682-692
64. Thompson P.D., and Franklin B.A. From case report to meta-analysis-additional evidence for the benefits of exercise training in cardiac patients. Am J Med 116 (2004) 714-716
65. Malfatto G., Branzi G., Riva B., Sala L., Leonetti G., and Facchini M. Recovery of cardiac autonomic responsiveness with low-intensity physical training in patients with chronic heart failure. Eur J Heart Fail 4 (2002) 159-166
66. Belardinelli R., Georgiou D., Cianci G., and Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 99 (1999) 1173-1182
67. Cahalin L.P., Semigran M.J., and Dec G.W. Inspiratory muscle training in patients with chronic heart failure awaiting cardiac transplantation: results of a pilot clinical trial. Phys Ther 77 (1997) 830-838
68. Gottlieb S.S., Fisher M.L., Freudenberger R., et al. Effects of exercise training on peak performance and quality of life in congestive heart failure patients. J Card Fail 5 (1999) 188-194
69. Hambrecht R., Fiehn E., Weigl C., et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 98 (1998) 2709-2715
70. Kiilavuori K., Naveri H., Leinonen H., and Harkonen M. The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. Eur Heart J 20 (1999) 456-464
71. McConnell T.R., Mandak J.S., Sykes J.S., Fesniak H., and Dasgupta H. Exercise training for heart failure patients improves respiratory muscle endurance, exercise tolerance, breathlessness, and quality of life. J Cardiopulm Rehabil 23 (2003) 10-16
72. McKelvie R.S., Teo K.K., Roberts R., et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J 144 (2002) 23-30
73. Pietila M., Malminiemi K., Vesalainen R., et al. Exercise training in chronic heart failure: beneficial effects on cardiac (11)C-hydroxyephedrine PET, autonomic nervous control, and ventricular repolarization. J Nucl Med 43 (2002) 773-779
74. Pu C.T., Johnson M.T., Forman D.E., et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol 90 (2001) 2341-2350
75. Schulze P.C., Gielen S., Schuler G., and Hambrecht R. Chronic heart failure and skeletal muscle catabolism: effects of exercise training. Int J Cardiol 85 (2002) 141-149
76. Smart N., and Marwick T.H. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med 116 (2004) 693-706
77. Ades P.A., Green N.M., and Coello C.E. Effects of exercise and cardiac rehabilitation on cardiovascular outcomes. Cardiol Clin 21 (2003) 435-448
78. Stewart K.J., Badenhop D., Brubaker P.H., Keteyian S.J., and King M. Cardiac rehabilitation following percutaneous revascularization, heart transplant, heart valve surgery, and for chronic heart failure. Chest 123 (2003) 2104-2111
79. Piepoli M.F., Davos C., Francis D.P., and Coats A.J. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 328 (2004) 189
80. Erbs S., Linke A., Gielen S., et al. Exercise training in patients with severe chronic heart failure: impact on left ventricular performance and cardiac size. A retrospective analysis of the Leipzig Heart Failure Training Trial. Eur J Cardiovasc Prev Rehabil 10 (2003) 336-344
81. Georgiou D., Chen Y., Appadoo S., et al. Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. Am J Cardiol 87 (2001) 984-988
82. Giannuzzi P., Temporelli P.L., Corra U., and Tavazzi L. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation 108 (2003) 554-559
83. Hambrecht R., Gielen S., Linke A., et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 283 (2000) 3095-3101
84. Quan S.F., and Gersh B.J. Cardiovascular consequences of sleep-disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 109 (2004) 951-957
85. Leung R.S., and Bradley T.D. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 164 (2001) 2147-2165
86. Ponikowski P., Chua T.P., Piepoli M., et al. Chemoreceptor dependence of very low frequency rhythms in advanced chronic heart failure. Am J Physiol 272 (1997) H438-H447
87. Younes M. The pathophysiologic basis of central apnea and periodic breathing. Curr Pulmonol 19 (1989) 265-326
88. Javaheri S., Parker T.J., Liming J.D., et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 97 (1998) 2154-2159
89. Sin D.D., Fitzgerald F., Parker J.D., Newton G., Floras J.S., and Bradley T.D. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 160 (1999) 1101-1106
90. Laaban J.P., Pascal-Sebaoun S., Bloch E., Orvoen-Frija E., Oppert J.M., and Huchon G. Left ventricular systolic dysfunction in patients with obstructive sleep apnea syndrome. Chest 122 (2002) 1133-1138
91. Parker J.D., Brooks D., Kozar L.F., et al. Acute and chronic effects of airway obstruction on canine left ventricular performance. Am J Respir Crit Care Med 160 (1999) 1888-1896
92. Carlson J.T., Hedner J., Elam M., Ejnell H., Sellgren J., and Wallin B.G. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 103 (1993) 1763-1768
93. Lanfranchi P.A., Braghiroli A., Bosimini E., et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 99 (1999) 1435-1440
94. Wilcox I., McNamara S.G., Wessendorf T., Willson G.N., Piper A.J., and Sullivan C.E. Prognosis and sleep disordered breathing in heart failure. Thorax 53 suppl 3 (1998) S33-S36
95. Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation 101 (2000) 392-397
96. Lanfranchi P.A., Somers V.K., Braghiroli A., Corra U., Eleuteri E., and Giannuzzi P. Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk. Circulation 107 (2003) 727-732
97. Krachman S.L., D'Alonzo G.E., Berger T.J., and Eisen H.J. Comparison of oxygen therapy with nasal continuous positive airway pressure on Cheyne-Stokes respiration during sleep in congestive heart failure. Chest 116 (1999) 1550-1557
98. Bradley T.D., Holloway R.M., McLaughlin P.R., Ross B.L., Walters J., and Liu P.P. Cardiac output response to continuous positive airway pressure in congestive heart failure. Am Rev Respir Dis 145 (1992) 377-382
99. Buckle P., Millar T., and Kryger M. The effect of short-term nasal CPAP on Cheyne-Stokes respiration in congestive heart failure. Chest 102 (1992) 31-35
100. Kaneko Y., Floras J.S., Usui K., et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348 (2003) 1233-1241
101. Malone S., Liu P.P., Holloway R., Rutherford R., Xie A., and Bradley T.D. Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure. Lancet 338 (1991) 1480-1484
102. Mehta S., Liu P.P., Fitzgerald F.S., Allidina Y.K., and Douglas B.T. Effects of continuous positive airway pressure on cardiac volumes in patients with ischemic and dilated cardiomyopathy. Am J Respir Crit Care Med 161 (2000) 128-134
103. Naughton M.T., Liu P.P., Bernard D.C., Goldstein R.S., and Bradley T.D. Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure. Am J Respir Crit Care Med 151 (1995) 92-97
104. Naughton M.T., Rahman M.A., Hara K., Floras J.S., and Bradley T.D. Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure. Circulation 91 (1995) 1725-1731
105. Naughton M.T., Benard D.C., Liu P.P., Rutherford R., Rankin F., and Bradley T.D. Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 152 (1995) 473-479
106. Tkacova R., Liu P.P., Naughton M.T., and Bradley T.D. Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure. J Am Coll Cardiol 30 (1997) 739-745
107. Pepperell J.C., Maskell N.A., Jones D.R., et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med 168 (2001) 1109-1114
108. Schadlich S., Konigs I., Kalbitz F., Blankenburg T., Busse H.J., and Schutte W. Cardiac efficiency in patients with Cheyne-Stokes respiration as a result of heart insufficiency during long-term nasal respiratory treatment with adaptive servo ventilation (AutoSet CS). [in German]. Z Kardiol 93 (2004) 454-462
109. Teschler H., Dohring J., Wang Y.M., and Berthon-Jones M. Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 164 (2001) 614-619
110. Sin D.D., Logan A.G., Fitzgerald F.S., Liu P.P., and Bradley T.D. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 102 (2000) 61-66
111. Bradley T.D., Logan A.G., Kimoff R.J., et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 (2005) 2025-2033
112. Cohn J.N., and Franciosa J.A. Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med 297 (1977) 254-258
113. Cotter G., Metzkor E., Kaluski E., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 (1998) 389-393
114. Colucci W.S., Elkayam U., Horton D.P., et al., Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
115. Hobbs R.E., Mills R.M., and Young J.B. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs 10 (2001) 935-942
116. Mills R.M., Hobbs R.E., and Young J.B. "BNP" for heart failure: role of nesiritide in cardiovascular therapeutics. Congest Heart Fail 8 (2002) 270-273
117. Protter A.A., Wallace A.M., Ferraris V.A., and Weishaar R.E. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 9 (1996) 432-436
118. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
119. Abramson B.L., Ando S., Notarius C.F., Rongen G.A., and Floras J.S. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure. Circulation 99 (1999) 1810-1815
120. Burger A.J., Elkayam U., Neibaur M.T., et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 88 (2001) 35-39
121. Burger A.J., Horton D.P., LeJemtel T., et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 144 (2002) 1102-1108
122. Marcus L.S., Hart D., Packer M., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94 (1996) 3184-3189
123. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 4 (1998) 37-44
124. Wang D.J., Dowling T.C., Meadows D., et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110 (2004) 1620-1625
125. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
126. Keating G.M., and Goa K.L. Nesiritide: a review of its use in acute decompensated heart failure. Drugs 63 (2003) 47-70
127. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
128. Yancy C.W., Saltzberg M.T., Berkowitz R.L., et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 94 (2004) 595-601
129. Dorn G.W., and Molkentin J.D. Manipulating cardiac contractility in heart failure: data from mice and men. Circulation 109 (2004) 150-158
130. Feldman A.M. Classification of positive inotropic agents. J Am Coll Cardiol 22 (1993) 1223-1227
131. Stevenson L.W. Clinical use of inotropic therapy for heart failure: looking backward or forward?. Part I: inotropic infusions during hospitalization. Circulation 108 (2003) 367-372
132. Cowley A.J., Skene A.M., and Enoximone Investigators. Treatment of severe heart failure: quantity or quality of life?. A trial of enoximone. Br Heart J 72 (1994) 226-230
133. Sharma M., and Teerlink J.R. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr Opin Cardiol 19 (2004) 254-263
134. Thackray S., Easthaugh J., Freemantle N., and Cleland J.G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 4 (2002) 515-529
135. Pozen R.G., DiBianco R., Katz R.J., Bortz R., Myerburg R.J., and Fletcher R.D. Myocardial metabolic and hemodynamic effects of dobutamine in heart failure complicating coronary artery disease. Circulation 63 (1981) 1279-1285
136. Campana C., Scelsi L., and Serio A. Infusion therapy in severe heart failure. A reappraisal. Ital Heart J 4 suppl 2 (2003) 15S-21S
137. Chatterjee K., and De M.T. Role of nonglycosidic inotropic agents: indications, ethics, and limitations. Med Clin N Am 87 (2003) 391-418
138. Felker G.M., and O'Connor C.M. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 142 (2001) 393-401
139. Bristow M.R. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 22 suppl A (1993) 61A-71
140. Bristow M.R. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80 (1997) 26L-40
141. Bristow M.R., Ginsburg R., Minobe W., et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307 (1982) 205-211
142. Fowler M.B., Laser J.A., Hopkins G.L., Minobe W., and Bristow M.R. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74 (1986) 1290-1302
143. Goldberg L.I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 24 (1972) 1-29
144. Goldberg L.I., Volkman P.H., and Kohli J.D. A comparison of the vascular dopamine receptor with other dopamine receptors. Annu Rev Pharmacol Toxicol 18 (1978) 57-79
145. Lokhandwala M.F., and Barrett R.J. Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. J Auton Pharmacol 2 (1982) 189-215
146. Rajfer S.I., and Goldberg L.I. Dopamine in the treatment of heart failure. Eur Heart J 3 suppl D (1982) 103-106
147. Lowes B.D., Tsvetkova T., Eichhorn E.J., Gilbert E.M., and Bristow M.R. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 81 (2001) 141-149
148. Metra M., Nodari S., D'Aloia A., et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40 (2002) 1248-1258
149. Akhtar N., Mikulic E., Cohn J.N., and Chaudhry M.H. Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol 36 (1975) 202-205
150. Leier C.V., Webel J., and Bush C.A. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 56 (1977) 468-472
151. Meyer S.L., Curry G.C., Donsky M.S., Twieg D.B., Parkey R.W., and Willerson J.T. Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease. Am J Cardiol 38 (1976) 103-108
152. Unverferth D.A., Blanford M., Kates R.E., and Leier C.V. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med 69 (1980) 262-266
153. Bristow M.R., Port J.D., Hershberger R.E., Gilbert E.M., and Feldman A.M. The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. Eur Heart J 10 suppl B (1989) 45-54
154. Colucci W.S., Denniss A.R., Leatherman G.F., et al. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. J Clin Invest 81 (1988) 1103-1110
155. Burger A.J., Horton D.P., LeJemtel T., et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 144 (2002) 1102-1108
156. Puddu P.E., Papalia U., Schiariti M., and Usta C. Dobutamine effects on spontaneous variability of ventricular arrhythmias in patients with severe chronic heart failure: the Italian Multicenter Study. Ital Heart J (2004) 693-701
157. Baim D.S., McDowell A.V., Cherniles J., et al. Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure. N Engl J Med 309 (1983) 748-756
158. Cowley A.J., Stainer K., Fullwood L., Muller A.F., and Hampton J.R. Effects of enoximone in patients with heart failure uncontrolled by captopril and diuretics. Int J Cardiol 28 suppl 1 (1990) S45-S52
159. Herrmann H.C., Ruddy T.D., Dec G.W., Strauss H.W., Boucher C.A., and Fifer M.A. Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside. Circulation 75 (1987) 1214-1221
160. Klocke R.K., Mager G., Kux A., Hopp H.W., and Hilger H.H. Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. Am Heart J 121 (1991) 1965-1973
161. Rettig G.F., and Schieffer H.J. Acute effects of intravenous milrinone in heart failure. Eur Heart J 10 suppl C (1989) 39-43
162. Luo W., Grupp I.L., Harrer J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75 (1994) 401-409
163. Anderson J.L. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 121 (1991) 1956-1964
164. Gage J., Rutman H., Lucido D., and LeJemtel T.H. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74 (1986) 367-373
165. Gilbert E.M., Hershberger R.E., Wiechmann R.J., Movsesian M.A., and Bristow M.R. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 108 (1995) 1524-1532
166. Uretsky B.F., Lawless C.E., Verbalis J.G., Valdes A.M., Kolesar J.A., and Reddy P.S. Combined therapy with dobutamine and amrinone in severe heart failure. Improved hemodynamics and increased activation of the renin-angiotensin system with combined intravenous therapy. Chest 92 (1987) 657-662
167. Bristow M.R., Shakar S.F., Linseman J.V., and Lowes B.D. Inotropes and beta-blockers: is there a need for new guidelines?. J Card Fail 7 suppl 1 (2001) 8-12
168. Hauptman P.J., Woods D., and Prirzker M.R. Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clin Cardiol 25 (2002) 247-249
169. Kumar A., Choudhary G., Antonio C., et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 142 (2001) 512-515
170. Shakar S.F., and Bristow M.R. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep 3 (2001) 224-231
171. Shakar S.F., Abraham W.T., Gilbert E.M., et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 31 (1998) 1336-1340
172. Zampino M., O'Connor C.M., Gattis W.A., Adams Jr. K.F., and Gheorghiade M. Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial. Am Heart J 145 suppl (2003) S62-S66
173. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77 (1995) 107-113
174. 2+ sensitizers-update 2001. Cardiovasc Drugs Ther 15 (2001) 397-403
175. Hasenfuss G., Pieske B., Castell M., Kretschmann B., Maier L.S., and Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98 (1998) 2141-2147
176. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al., Study investigators. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102 (2000) 2222-2227
177. Cleland J.G., and McGowan J. Levosimendan: a new era for inodilator therapy for heart failure?. Curr Opin Cardiol 17 (2002) 257-265
178. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 (2002) 196-202
179. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1903-1912
180. Kivikko M., Lehtonen L., and Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 107 (2003) 81-86
181. Lehtonen L., and Sundberg S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 58 (2002) 449-452
182. Innes C.A., and Wagstaff A.J. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 63 (2003) 2651-2671
183. Brozena S.C., Twomey C., Goldberg L.R., et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant 23 (2004) 1082-1086
184. Canver C.C., and Chanda J. Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. Ann Thorac Surg 69 (2000) 1823-1826
185. Capomolla S., Febo O., Opasich C., et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 3 (2001) 601-610
186. Rapezzi C., Bracchetti G., Branzi A., and Magnani B. The case against outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant 19 suppl (2000) S58-S63
187. Upadya S., Lee F.A., Saldarriaga C., et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant 23 (2004) 466-472
188. Jimenez J., Jara J., Bednar B., Bauerlein J., and Mallon S. Long-term (>8 weeks) home inotropic therapy as destination therapy in patients with advanced heart failure or as bridge to heart transplantation. Int J Cardiol 99 (2005) 47-50
189. Lopez-Candales A.L., Carron C., and Schwartz J. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes. Clin Cardiol 27 (2004) 23-28
190. Mehra M.R., and Uber P.A. The dilemma of late-stage heart failure. Rationale for chronic parenteral inotropic support. Cardiol Clin 19 (2001) 627-636
191. Miller L.W., Merkle E.J., and Herrmann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med 18 suppl (1990) S30-S33
192. Pantilat S.Z., and Steimle A.E. Palliative care for patients with heart failure. JAMA 291 (2004) 2476-2482
193. Sindone A.P., Keogh A.M., Macdonald P.S., McCosker C.J., and Kaan A.F. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J 134 (1997) 889-900
194. Stevenson L.W. Clinical use of inotropic therapy for heart failure: looking backward or forward?. Part II: chronic inotropic therapy. Circulation 108 (2003) 492-497
195. Stevenson L.W., Miller L.W., Svigne-Nickens P., et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 110 (2004) 975-981
196. Applefeld M.M., Newman K.A., Grove W.R., et al. Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol 51 (1983) 455-458
197. Cesario D., Clark J., and Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 135 (1998) 121-129
198. Leier C.V., and Binkley P.F. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 41 (1998) 207-224
199. Marius-Nunez A.L., Heaney L., Fernandez R.N., et al. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 132 (1996) 805-808
200. Oliva F., Latini R., Politi A., et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 138 (1999) 247-253
201. Teerlink J.R., Jalaluddin M., Anderson S., et al., PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. Circulation 101 (2000) 40-46
202. Uretsky B.F., Jessup M., Konstam M.A., et al., Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 82 (1990) 774-780
203. Woods T.D., and Prisant L.M. Pulsed inotropic therapy in chronic congestive heart failure: a review of the literature. Am J Ther 7 (2000) 375-380
204. Young J.B., and Moen E.K. Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant 19 suppl (2000) S49-S57
205. Krell M.J., Kline E.M., Bates E.R., et al. Intermittent ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 112 (1986) 787-791
206. Elis A., Bental T., Kimchi O., Ravid M., and Lishner M. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 63 (1998) 682-685
207. DiBianco R., Shabetai R., Kostuk W., et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320 (1989) 677-683
208. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial InvestigatorsN Engl J Med 339 (1998) 1810-1816
209. DiBianco R., Shabetai R., Silverman B.D., Leier C.V., and Benotti J.R. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol 4 (1984) 855-866
210. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 336 (1990) 1-6
211. Hampton J.R., Van Veldhuisen D.J., Kleber F.X., et al., Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 349 (1997) 971-977
212. Packer M., Carver J.R., Rodeheffer R.J., et al., The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325 (1991) 1468-1475
213. Terracciano C.M., Hardy J., Birks E.J., Khaghani A., Banner N.R., and Yacoub M.H. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 109 (2004) 2263-2265
214. Dor V. Surgical remodeling of left ventricle. Surg Clin N Am 84 (2004) 27-43
215. Mann D.L., Acker M.A., Jessup M., Sabbah H.N., Starling R.C., and Kubo S.H. Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York Heart Association class III-IV heart failure. J Card Fail 10 (2004) 185-192
216. Shelton R.J., Velavan P., Nikitin N.P., et al. Clinical trials update from the American Heart Association meeting: ACORN-CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, vitamin E meta-analysis, ESCAPE, CARP, and SCD-HeFT cost-effectiveness study. Eur J Heart Fail 7 (2005) 127-135
217. Soran O. A new treatment modality in heart failure enhanced external counterpulsation (EECP). Cardiol Rev 12 (2004) 15-20
218. Soran O., Kennard E.D., Kelsey S.F., Holubkov R., Strobeck J., and Feldman A.M. Enhanced external counterpulsation as treatment for chronic angina in patients with left ventricular dysfunction: a report from the International EECP Patient Registry (IEPR). Congest Heart Fail 8 (2002) 297-302
219. Hassink R.J., Dowell J.D., de la Brutel R.A., Doevendans P.A., and Field L.J. Stem cell therapy for ischemic heart disease. Trends Mol Med 9 (2003) 436-441
220. Kizana E., and Alexander I.E. Cardiac gene therapy: therapeutic potential and current progress. Curr Gene Ther 3 (2003) 418-451
221. Orlic D., Kajstura J., Chimenti S., et al. Bone marrow cells regenerate infarcted myocardium. Nature 410 (2001) 701-705
222. Orlic D., Kajstura J., Chimenti S., et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98 (2001) 10344-10349
223. Perin E.C., Dohmann H.F., Borojevic R., et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107 (2003) 2294-2302
224. Tse H.F., Kwong Y.L., Chan J.K., Lo G., Ho C.L., and Lau C.P. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361 (2003) 47-49
225. Alderman E.L., Fisher L.D., Litwin P., et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 68 (1983) 785-795
226. Shah P.J., Hare D.L., Raman J.S., et al. Survival after myocardial revascularization for ischemic cardiomyopathy: a prospective ten-year follow-up study. J Thorac Cardiovasc Surg 126 (2003) 1320-1327
227. Joyce D., Loebe M., Noon G.P., et al. Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Curr Opin Cardiol 18 (1997) 454-457
228. Athanasuleas C.L., Buckberg G.D., Stanley A.W., et al. Surgical ventricular restoration in the treatment of congestive heart failure due to postinfarction ventricular dilation. J Am Coll Cardiol 44 (2004) 1439-1445
229. Dor V. Reconstructive left ventricular surgery for postischemic akinetic dilatation. Semin Thorac Cardiovasc Surg 9 (1997) 139-145
230. Di D.M., Sabatier M., Dor V., et al. Effects of the Dor procedure on left ventricular dimension and shape and geometric correlates of mitral regurgitation one year after surgery. J Thorac Cardiovasc Surg 121 (2001) 91-96
231. Bach D.S., and Bolling S.F. Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. Am J Cardiol 78 (1996) 966-969
232. Wu A.H., Aaronson K.D., Bolling S.F., Pagani F.D., Welch K., and Koelling T.M. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitatiomortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45 (2005) 381-387
233. Mehra M.R., and Griffith B.P. Is mitral regurgitation a viable treatment target in heart failure?. The plot just thickened. J Am Coll Cardiol 45 (2005) 388-390
234. Remme W.J., Swedberg K., and Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Eur J Heart Fail 4 (2002) 11-22
235. Packer M., Poole-Wilson P.A., Armstrong P.W., et al., ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 (1999) 2312-2318
236. Carson P., Ziesche S., Johnson G., Cohn J.N., and Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 5 (1999) 178-187
237. Omland T., Aakvaag A., Bonarjee V.V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93 (1996) 1963-1969
238. Hartmann F., Packer M., Coats A.J., et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110 (2004) 1780-1786
239. Maisel A. B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail 7 (2001) 183-193
240. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106 (2002) 416-422
241. Gardner R.S., Ozalp F., Murday A.J., Robb S.D., and McDonagh T.A. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
242. Bruins S., Fokkema M.R., Romer J.W., et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50 (2004) 2052-2058
243. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
244. Antman E.M. Decision making with cardiac troponin tests. N Engl J Med 346 (2002) 2079-2082
245. Ishii J., Nomura M., Nakamura Y., et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 89 (2002) 691-695
246. Perna E.R., Macin S.M., Canella J.P., et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 110 (2004) 2376-2382
247. Ishii J., Cui W., Kitagawa F., et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 49 (2003) 2020-2026
248. Campana C., Gavazzi A., Berzuini C., et al. Predictors of prognosis in patients awaiting heart transplantation. J Heart Lung Transplant 12 (1993) 756-765
249. Aaronson K.D., Schwartz J.S., Chen T.M., Wong K.L., Goin J.E., and Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 (1997) 2660-2667
250. Gardner R.S., Henderson G., and McDonagh T.A. The prognostic use of right heart catheterization data in patients with advanced heart failure: how relevant are invasive procedures in the risk stratification of advanced heart failure in the era of neurohormones?. J Heart Lung Transplant 24 (2005) 303-309
251. Steimle A.E., Stevenson L.W., Chelimsky-Fallick C., et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 96 (1997) 1165-1172
252. Stevenson L.W., Dracup K.A., and Tillisch J.H. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol 63 (1989) 461-464
253. Binanay C., Califf R.M., Hasselblad V., et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294 (2005) 1625-1633
254. Kirklin J.K., Naftel D.C., Kirklin J.W., Blackstone E.H., White-Williams C., and Bourge R.C. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 7 (1998) 331-336
255. Chen J.M., Levin H.R., Michler R.E., Prusmack C.J., Rose E.A., and Aaronson K.D. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 114 (1997) 627-634
256. Costard-Jackle A., and Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19 (1992) 48-54
257. Dreyfus G., Jebara V.A., Guillemain R., Amrein C., and Carpentier A.F. Improved evaluation of pulmonary vascular resistance prior to heart transplantation. Transplant Proc 21 (1989) 2559-2561
258. Pagani F.D., Lynch W., Swaniker F., et al. Extracorporeal life support to left ventricular assist device bridge to heart transplant: a strategy to optimize survival and resource utilization. Circulation 100 suppl II (1999) II-206-II-210
259. Frazier O.H., Rose E.A., Oz M.C., et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 122 (2001) 1186-1195
260. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
261. Michalsen A., Konig G., and Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 80 (1998) 437-441
262. Rich M.W., Beckham V., Wittenberg C., et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333 (1995) 1190-1195
263. Stewart S., Marley J.E., and Horowitz J.D. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 354 (1999) 1077-1083
264. McAlister F.A., Stewart S., Ferrua S., and McMurray J.J. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 44 (2004) 810-819
265. DeBusk R.F., Miller N.H., Parker K.M., et al. Care management for low-risk patients with heart failure: a randomized, controlled trial. Ann Intern Med 141 (2004) 606-613
266. Atienza F., Anguita M., Martinez-Alzamora N., et al. Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program. Eur J Heart Fail 6 (2004) 643-652
267. Tsuyuki R.T., McKelvie R.S., Arnold J.M., et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 161 (2001) 2337-2342